Aarey Drugs & Pharmaceuticals growth over the years

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Compounded a year1 yr3 yr
Revenue−0.4%+96.2%
EBITDA+218.8%+67.4%
Net Income−1.4%+100.2%
EPS (adj.)−1.4%+100.2%
Total Assets+24.8%+0.7%
Total Equity+8.6%+8.6%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

AAREYDRUGS₹108.05

Aarey Drugs & Pharmaceuticals Limited

· Pharma & Health
₹ CrorePeersNECLIFENATCAPSUQMEDICAMEQMEDICOBALPHARMAALPAKREBSBIOHALEOSLABSMcap ₹307 Cr
Annuals · FY-end closes
Compounded Growth
Annuals · CAGR %
1Y
CAGR
3Y
CAGR
Revenue-0.4+96.2
EBITDA+218.8+67.4
Net Income-1.4+100.2
EPS (adj.)-1.4+100.2
Total Assets+24.8+0.7
Total Equity+8.6+8.6
CAGR from filed annuals — needs positive start & end values.
« ‹ › »Latest: FY26 · StandaloneFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.